Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company based in Tarrytown, New York, that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

NASDAQ REGN

$368.87 0.28 (0.08)%

High 370.73 Low 367.25 Volume 144,318 Market Cap 38.42B
03/23/17 11:59 AM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Mar 22

    U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis

    Read on
  • Mar 14

    Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017

    Read on

EVENTS

  • ACC 2017
    Mar 17, 2017

  • Regeneron Corporate Presentation – March 2017
    Mar 10, 2017

Events & Presentations

NASDAQ REGN

$368.87 0.28 (0.08)%

High 370.73 Low 367.25 Volume 144,318 Market Cap 38.42B
03/23/17 11:59 AM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information